AIM Targeted TherapiesTM will be presenting at Biotech Showcase-2019 in San Francisco
Key Biscayne, FL. –AIM Targeted TherapiesTM (AIM-TT) today announced that it will present at Biotech Showcase™ 2019, on Tuesday 8 January at 11 am at the Hilton San Francisco Union Square, in Franciscan B (Ballroom Level).
Dr Glenn Abrahmsohn, CEO, will present the company’s breakthrough innovations in pain-control and antimicrobial-healing to investors.
AIM-TT has two patented medical formulations feelingTM (BDA 12) and ZAPPTM that address two of the biggest crises in America today: opioid over-use and antimicrobial resistance.
feelingTM, for pain control, not only reverses anesthesia-related numbness after surgical/dental procedures, but also maintains pain relief. This reduces the need to use opioid-based analgesics. Data suggests that the mechanism of action involves a molecular switch resulting in Local Anesthesia Analgesia Without Numbness (“LAAWON”).
ZAPPTM, an antimicrobial and healing medication, possesses strong antibacterial, antifungal, and antiviral activities. The formulation can be adapted into a wound healing ointment/paste and oronasal medications. As a topical wound healing ointment/paste ZAPP can heal major, chronic and burn wounds with almost no scarring. For oronasal therapies, ZAPPTM can be formulated as a mouth rinse and nasal spray for post-surgical wound cleansing and to treat symptoms of cold, flu and sinusitis.
The company is seeking additional funding to further develop both products and take them to market.
About AIM Targeted Therapies
AIM-TT is developing new solutions to address two of the most pressing needs in public health: opioid addiction and antimicrobial resistance. The founders have spent over 20 years developing these solutions with extremely promising results. Collectively, the executive team brings over 100 years of experience in dentistry, entrepreneurship, and executive leadership in the biopharmaceutical industry. AIM-TT operates out of Key Biscayne, Florida
Forward-Looking Statements
Statements regarding AIM-TT intentions, strategy, hopes, beliefs, expectations or predictions of the future are forward-looking statements. These forward-looking statements are predictions based on AIM-TT’s current expectations. It is important to note that future events and actual results, financial or otherwise, could differ materially from those projected in such forward-looking statements. AIM-TT does not undertake an obligation to update or revise any forward-looking statement.
Corporate Contact
Glenn Abrahmsohn, L.D.S., R.C.S. (Eng.)
Founder & CEO
T: +1 305 361 0778